RXRXRECURSION PHARMACEUTICALS, ...

Nasdaq recursion.com


$ 6.01 $ 0.02 (0.33 %)    

Monday, 09-Sep-2024 10:57:03 EDT
QQQ $ 451.41 $ -1.12 (-0.25 %)
DIA $ 408.32 $ 0.99 (0.24 %)
SPY $ 543.97 $ -0.70 (-0.13 %)
TLT $ 99.80 $ 0.42 (0.42 %)
GLD $ 230.72 $ -0.54 (-0.23 %)
$ 5.92
$ 5.99
$ 5.92 x 146
$ 6.00 x 304
$ 5.92 - $ 6.10
$ 4.97 - $ 15.74
4,577,882
na
1.66B
$ 2.28
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-08-2024 06-30-2024 10-Q
2 05-09-2024 03-31-2024 10-Q
3 02-29-2024 12-31-2023 10-K
4 11-09-2023 09-30-2023 10-Q
5 08-08-2023 06-30-2023 10-Q
6 05-08-2023 03-31-2023 10-Q
7 02-27-2023 12-31-2022 10-K
8 11-08-2022 09-30-2022 10-Q
9 08-09-2022 06-30-2022 10-Q
10 05-10-2022 03-31-2022 10-Q
11 03-23-2022 12-31-2021 10-K
12 11-10-2021 09-30-2021 10-Q
13 08-13-2021 06-30-2021 10-Q
14 05-12-2021 03-31-2021 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 needham-maintains-buy-on-recursion-pharmaceuticals-lowers-price-target-to-11

Needham analyst Gil Blum maintains Recursion Pharmaceuticals (NASDAQ:RXRX) with a Buy and lowers the price target from $16 t...

 jefferies-maintains-hold-on-recursion-pharmaceuticals-lowers-price-target-to-6

Jefferies analyst Dennis Ding maintains Recursion Pharmaceuticals (NASDAQ:RXRX) with a Hold and lowers the price target from...

 leerink-partners-maintains-market-perform-on-recursion-pharmaceuticals-lowers-price-target-to-8

Leerink Partners analyst Mani Foroohar maintains Recursion Pharmaceuticals (NASDAQ:RXRX) with a Market Perform and lowers th...

 recursion-pharmaceuticals-stock-is-sliding-tuesday-whats-going-on

Recursion Pharmaceuticals Inc (NASDAQ:RXRX) shares are trading lower. The company on Tuesday announced Phase 2 data for an inve...

 needham-maintains-buy-on-recursion-pharmaceuticals-lowers-price-target-to-16

Needham analyst Gil Blum maintains Recursion Pharmaceuticals (NASDAQ:RXRX) with a Buy and lowers the price target from $17 t...

 ai-powered-drug-discovery-firm-exscientia-to-merge-with-nvidia-partner-recursion-pharmaceuticals

Exscientia merges with Recursion Pharmaceuticals in an all-stock deal. The new entity, named Recursion, will focus on industria...

Core News & Articles

Expect 10 Clinical Readouts In 18 Months, $200M In Milestone Payments Over 24 Months, $20B Potentially Overall, $850M Cash On H...

 keybanc-maintains-overweight-on-recursion-pharmaceuticals-lowers-price-target-to-12

Keybanc analyst Scott Schoenhaus maintains Recursion Pharmaceuticals (NASDAQ:RXRX) with a Overweight and lowers the price ta...

 why-recursion-pharmaceuticals-stock-is-tumbling-thursday

Recursion announced that it intends to offer and sell 30,769,230 shares of its common stock for $6.50 per share in an underwri...

Core News & Articles
Market-Moving News for June 27th
06/27/2024 12:37:40

CASI: 92% | CASI Pharmaceuticals Announced Plan To Submit CID-103 IND Application; Also Announces Receipt Of A Non-binding Prop...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION